New triple therapy could extend lives in stomach cancer
NCT ID NCT06093425
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called TST001 added to standard chemotherapy and immunotherapy for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if the combination helps control the tumor longer and improves survival. About 820 adults whose tumors have a specific marker (Claudin18.2) will participate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- A lifeline for cancer caregivers: can simple phone support reduce their stress?
- Can a new drug combo shrink Hard-to-Treat tumors?